RT Journal Article
T1 SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19.
A1 Muñoz-Jurado, Ana
A1 Escribano, Begoña M
A1 Agüera, Eduardo
A1 Caballero-Villarraso, Javier
A1 Galvan, Alberto
A1 Tunez, Isaac
K1 Adjuvant treatments
K1 Disease-modifying therapies
K1 Immunity
K1 Multiple sclerosis
K1 Neuro-COVID
K1 SARS-CoV-2
AB The SARS-CoV-2 pandemic has raised particular concern for people with Multiple Sclerosis, as these people are believed to be at increased risk of infection, especially those being treated with disease-modifying therapies. Therefore, the objective of this review was to describe how COVID-19 affects people who suffer from Multiple Sclerosis, evaluating the risk they have of suffering an infection by this virus, according to the therapy to which they are subjected as well as the immune response of these patients both to infection and vaccines and the neurological consequences that the virus can have in the long term. The results regarding the increased risk of infection due to treatment are contradictory. B-cell depletion therapies may cause patients to have a lower probability of generating a detectable neutralizing antibody titer. However, more studies are needed to help understand how this virus works, paying special attention to long COVID and the neurological symptoms that it causes.
PB Springer
YR 2022
FD 2022-06-14
LK http://hdl.handle.net/10668/20019
UL http://hdl.handle.net/10668/20019
LA en
NO Muñoz-Jurado A, Escribano BM, Agüera E, Caballero-Villarraso J, Galván A, Túnez I. SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19. J Neurol. 2022 Sep;269(9):4581-4603
DS RISalud
RD Apr 5, 2025